<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome - Tso, LO - 2020 | Cochrane Library</title> <meta content="Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome - Tso, LO - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006105.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome - Tso, LO - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006105.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006105.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome" name="citation_title"/> <meta content="Leopoldo O Tso" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="leotso@uol.com.br" name="citation_author_email"/> <meta content="Michael F Costello" name="citation_author"/> <meta content="School of Women's and Children's Health, UNSW and Royal Hospital for Women and IVF Australia" name="citation_author_institution"/> <meta content="Luiz Eduardo T Albuquerque" name="citation_author"/> <meta content="Fertivitro Centro de Reprodução Humana" name="citation_author_institution"/> <meta content="Regis B Andriolo" name="citation_author"/> <meta content="Universidade do Estado do Pará" name="citation_author_institution"/> <meta content="Cristiane R Macedo" name="citation_author"/> <meta content="Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD006105.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006105.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006105.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006105.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abortion, Spontaneous [epidemiology, prevention &amp; control]; Bias; Confidence Intervals; *Fertilization in Vitro; Hyperandrogenism [*drug therapy]; Hyperinsulinism [*drug therapy]; Hypoglycemic Agents [adverse effects, *therapeutic use]; Live Birth [*epidemiology]; Metformin [adverse effects, *therapeutic use]; Ovarian Hyperstimulation Syndrome [epidemiology, prevention &amp; control]; Ovulation Induction [methods]; Placebos [therapeutic use]; Polycystic Ovary Syndrome [*complications]; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006105.pub4&amp;doi=10.1002/14651858.CD006105.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006105\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006105\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006105.pub4",title:"Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome",firstPublishedDate:"Dec 21, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006105.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006105.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006105.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006105.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006105.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006105.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006105.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006105.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006105.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006105.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11174 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006105.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/appendices#CD006105-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/supinfo/CD006105StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/supinfo/CD006105StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#CD006105-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Leopoldo O Tso</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#CD006105-cr-0005">Michael F Costello</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#CD006105-cr-0006">Luiz Eduardo T Albuquerque</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#CD006105-cr-0007">Regis B Andriolo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information#CD006105-cr-0008">Cristiane R Macedo</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information/en#CD006105-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006105.pub4">https://doi.org/10.1002/14651858.CD006105.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006105-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006105-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006105-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006105-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006105-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD006105-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006105-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006105-abs-0001" lang="en"> <section id="CD006105-sec-0001"> <h3 class="title" id="CD006105-sec-0001">Background</h3> <p>The use of insulin‐sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied. Metformin reduces hyperinsulinaemia and suppresses the excessive ovarian production of androgens. It is suggested that as a consequence metformin could improve assisted reproductive techniques (ART) outcomes, such as ovarian hyperstimulation syndrome (OHSS), pregnancy, and live birth rates. </p> </section> <section id="CD006105-sec-0002"> <h3 class="title" id="CD006105-sec-0002">Objectives</h3> <p>To determine the effectiveness and safety of metformin as a co‐treatment during IVF or intracytoplasmic sperm injection (ICSI) in achieving pregnancy or live birth in women with PCOS. </p> </section> <section id="CD006105-sec-0003"> <h3 class="title" id="CD006105-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL via the Cochrane Register of Studies Online (CRSO), MEDLINE, Embase, PsycINFO, LILACS, the trial registries for ongoing trials, and reference lists of articles (from inception to 13 February 2020). </p> </section> <section id="CD006105-sec-0004"> <h3 class="title" id="CD006105-sec-0004">Selection criteria</h3> <p>Types of studies: randomised controlled trials (RCTs) comparing metformin treatment with placebo or no treatment in women with PCOS who underwent IVF or ICSI treatment. </p> <p>Types of participants: women of reproductive age with anovulation due to PCOS with or without co‐existing infertility factors. </p> <p>Types of interventions: metformin administered before and during IVF or ICSI treatment.</p> <p>Primary outcome measures: live birth rate, incidence of ovarian hyperstimulation syndrome.</p> </section> <section id="CD006105-sec-0005"> <h3 class="title" id="CD006105-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected the studies, extracted the data according to the protocol, and assessed study quality. We assessed the overall quality of the evidence using the GRADE approach. </p> </section> <section id="CD006105-sec-0006"> <h3 class="title" id="CD006105-sec-0006">Main results</h3> <p>This updated review includes 13 RCTs involving a total of 1132 women with PCOS undergoing IVF/ICSI treatments. We stratified the analysis by type of ovarian stimulation protocol used (long gonadotrophin‐releasing hormone agonist (GnRH‐agonist) or short gonadotrophin‐releasing hormone antagonist (GnRH‐antagonist)) to determine whether the type of stimulation used influenced the outcomes. We did not perform meta‐analysis on the overall (both ovarian stimulation protocols combined) data for the outcomes of live birth and clinical pregnancy rates per woman because of substantial heterogeneity. </p> <p>In the long protocol GnRH‐agonist subgroup, the pooled evidence showed that we are uncertain of the effect of metformin on live birth rate per woman when compared with placebo/no treatment (risk ratio (RR) 1.30, 95% confidence interval (CI) 0.94 to 1.79; 6 RCTs; 651 women; I<sup>2</sup> = 47%; low‐quality evidence). This suggests that if the chance for live birth following placebo/no treatment is 28%, the chance following metformin would be between 27% and 51%. Only one study used short protocol GnRH‐antagonist and reported live birth rate. Metformin may reduce live birth rate compared with placebo/no treatment (RR 0.48, 95% CI 0.29 to 0.79; 1 RCT; 153 women; low‐quality evidence). This suggests that if the chance for live birth following placebo/no treatment is 43%, the chance following metformin would be between 13% and 34% (short GnRH‐antagonist protocol). We found that metformin may reduce the incidence of OHSS (RR 0.46, 95% CI 0.29 to 0.72; 11 RCTs; 1091 women; I<sup>2</sup> = 38%; low‐quality evidence). This suggests that for a woman with a 20% risk of OHSS without metformin, the corresponding risk using metformin would be between 6% and 14%. Using long protocol GnRH‐agonist stimulation, metformin may increase clinical pregnancy rate per woman compared with placebo/no treatment (RR 1.32, 95% CI 1.08 to 1.63; 10 RCTs; 915 women; I<sup>2</sup> = 13%; low‐quality evidence). Using short protocol GnRH‐antagonist, we are uncertain of the effect of metformin on clinical pregnancy rate per woman compared with placebo/no treatment (RR 1.38, 95% CI 0.21 to 9.14; 2 RCTs; 177 women; I<sup>2</sup> = 87%; very low‐quality evidence). </p> <p>We are uncertain of the effect of metformin on miscarriage rate per woman when compared with placebo/no treatment (RR 0.86, 95% CI 0.56 to 1.32; 8 RCTs; 821 women; I<sup>2</sup> = 0%; low‐quality evidence). Metformin may result in an increase in side effects compared with placebo/no treatment (RR 3.35, 95% CI 2.34 to 4.79; 8 RCTs; 748 women; I<sup>2</sup> = 0%; low‐quality evidence). </p> <p>The overall quality of evidence ranged from very low to low. The main limitations were inconsistency, risk of bias, and imprecision. </p> </section> <section id="CD006105-sec-0007"> <h3 class="title" id="CD006105-sec-0007">Authors' conclusions</h3> <p>This updated review on metformin versus placebo/no treatment before or during IVF/ICSI treatment in women with PCOS found no conclusive evidence that metformin improves live birth rates. In a long GnRH‐agonist protocol, we are uncertain whether metformin improves live birth rates, but metformin may increase the clinical pregnancy rate. In a short GnRH‐antagonist protocol, metformin may reduce live birth rates, although we are uncertain about the effect of metformin on clinical pregnancy rate. Metformin may reduce the incidence of OHSS but may result in a higher incidence of side effects. We are uncertain of the effect of metformin on miscarriage rate per woman. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006105-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006105-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006105-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006105-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006105-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006105-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006105-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006105-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006105-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD006105-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006105-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006105-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006105-abs-0002" lang="en"> <h3>Metformin in women with polycystic ovary syndrome (PCOS) for improving fertility</h3> <p><b>Review question</b> </p> <p>The aim of this review was to determine if metformin improves live birth and clinical pregnancy rates and whether it reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in women with PCOS undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). </p> <p><b>Background</b> </p> <p>In women with PCOS there is a chronic failure or absence of ovulation (anovulation) and excessive production of male hormones (hyperandrogenism). The main symptoms of the disorder are irregular periods, infertility, hirsutism (excessive facial and body hair growth), and acne. PCOS is the most common endocrine disorder in women, affecting 5% to 10% of women of reproductive age. IVF could be an effective treatment option for infertility in women with PCOS who do not respond to ovulation induction treatments. In the first part of IVF treatment, ovarian stimulation using gonadotrophins is necessary to develop more mature oocytes in order to produce more good‐quality embryos to be transferred into the uterus. This overstimulation increases the risk of developing a serious complication known as ovarian hyperstimulation syndrome (OHSS). Strategies used during IVF treatments to decrease the risk of OHSS include: low‐dose gonadotrophin ovarian stimulation, metformin co‐treatment, use of gonadotrophin‐releasing hormone (GnRH)‐antagonist protocol instead of GnRH‐agonist, and use of GnRH‐agonist trigger to final oocyte maturation rather than the usual human chorionic gonadotrophin (hCG)‐trigger. </p> <p><b>Study characteristics</b> </p> <p>We included 13 randomised controlled trials (a type of study in which participants are assigned to one of two or more treatment groups using a random method) involving a total of 1132 women assigned to receive either metformin (570) or placebo (dummy treatment)/no treatment (563). The evidence is current to 13 February 2020. </p> <p><b>Key results</b> </p> <p>We divided the analysis by type of ovarian stimulation protocol used during the IVF treatment (long GnRH‐agonist or short GnRH‐antagonist) to determine whether the type of stimulation used influenced the outcomes. We are uncertain of the effect of metformin using long protocol GnRH‐agonist on live birth rates compared with placebo or no treatment, but metformin may increase clinical pregnancy rate with this type of ovarian stimulation protocol. Metformin may reduce the incidence of OHSS. We estimated that for a woman with a 28% chance of achieving a live birth (long protocol GnRH‐agonist) following placebo or no treatment, the chance following metformin would be between 27% and 51%. For a woman with a 28% chance of achieving a clinical pregnancy in long protocol GnRH‐agonist without metformin, the chance using metformin would be between 30% and 45%. </p> <p>For the short protocol GnRH‐antagonist, metformin may reduce live birth rate, and we are uncertain of its effect on clinical pregnancy and OHSS rates compared with placebo/no treatment. </p> <p>Overall, metformin may reduce the incidence of OHSS when compared with placebo/no treatment. For a woman with a 20% risk of OHSS without metformin, the corresponding risk using metformin would be between 6% and 14%. Side effects (mostly gastrointestinal) may be more common with metformin. We are uncertain of the effect of metformin on miscarriage rates when compared with placebo/no treatment. </p> <p><b>Quality of the evidence</b> </p> <p>The overall quality of evidence for the primary outcomes live birth rate and incidence of OHSS was low. We assessed the evidence as low for the secondary outcomes clinical pregnancy rate (long protocol GnRH‐agonist), miscarriage rate, and side effects, and very low for clinical pregnancy rate (short protocol GnRH‐antagonist). The main limitations were risk of bias and imprecise results. </p> <p><b>Conclusion</b> </p> <p>This updated review on metformin versus placebo/no treatment before or during IVF/ICSI treatment in women with PCOS found no clear evidence that metformin improves live birth rates: the effect of metformin is uncertain using long protocol GnRH‐agonist, but live birth rates may be reduced using short protocol GnRH‐antagonist. Metformin may increase clinical pregnancy rates using long protocol GnRH‐agonist, but we are uncertain of the effect using short protocol GnRH‐antagonist. Metformin may reduce the incidence of OHSS, but may result in a higher incidence of side effects. We are uncertain of the effect of metformin on miscarriage rate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006105-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006105-sec-0088"></div> <h3 class="title" id="CD006105-sec-0089">Implications for practice</h3> <section id="CD006105-sec-0089"> <p>This updated review on metformin versus placebo/no treatment before and during in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment in women with polycystic ovary syndrome (PCOS) found no conclusive evidence that metformin improves live birth rates. In a long gonadotrophin‐releasing hormone (GnRH)‐agonist protocol, we are uncertain whether metformin improves live birth rates, but metformin may increase clinical pregnancy rate. In a short GnRH‐antagonist protocol, metformin may reduce live birth rates, although we are uncertain of the effect of metformin on clinical pregnancy rate. Metformin may reduce the incidence of ovarian hyperstimulation syndrome (OHSS), but may result in a higher incidence of side effects. We are uncertain of the effect of metformin on miscarriage rate per woman. </p> </section> <h3 class="title" id="CD006105-sec-0090">Implications for research</h3> <section id="CD006105-sec-0090"> <p>Further large, well‐designed, and well‐executed randomised controlled trials with adequate power are needed to definitively answer the question of whether the use of metformin in women with PCOS undergoing assisted reproductive techniques (ART) improves live birth rate. All studies should report live birth rate (per woman), OHSS (per woman), and other adverse events. Only a few studies using short protocol GnRH‐antagonist comparing metformin with placebo or no treatment exist, therefore further studies using this type of protocol are required to determine the effect this comparison has on reproductive outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006105-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006105-sec-0008"></div> <div class="table" id="CD006105-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to placebo or no treatment in women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin compared to placebo or no treatment in women with polycystic ovary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome<br/><b>Setting:</b> Human reproduction center<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Live birth rate per woman ‐ long protocol GnRH‐agonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/>(0.94 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>651<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence for the effect of metformin on live birth rate per woman ‐ long protocol GnRH‐agonist is uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000<br/>(266 to 507) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Live birth rate per woman ‐ short protocol GnRH‐antagonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/>(0.29 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may reduce live birth rate per woman ‐ short protocol GnRH‐antagonist.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000<br/>(126 to 343) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of OHSS per woman</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.46<br/>(0.29 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1091<br/>(11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may reduce incidence of OHSS per woman.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/>(57 to 141) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical pregnancy rate per woman ‐ long protocol GnRH‐agonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(1.08 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>915<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may increase clinical pregnancy rate per woman ‐ long protocol GnRH‐agonist.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000<br/>(297 to 449) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical pregnancy rate per woman ‐ short protocol GnRH‐antagonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.38<br/>(0.21 to 9.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>177<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>5 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence for the effect of metformin on clinical pregnancy rate per woman ‐ short protocol GnRH‐antagonist is uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>612 per 1000<br/>(93 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Miscarriage rate per woman</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.56 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>821<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence for the effect of metformin on miscarriage rate per woman is uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(59 to 141) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Side effects per woman</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.35<br/>(2.34 to 4.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>748<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may result in an increase in side effects per woman.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(207 to 424) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>GnRH:</b> gonadotrophin‐releasing hormone; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded by one level for serious risk of bias: the majority of the RCTs have unclear or high risk of bias.<br/><sup>2</sup>Evidence downgraded by one level for serious imprecision: low number of events (total number of events &lt; 300) and 95% CI includes both appreciable effect and little or no effect.<br/><sup>3</sup>Evidence downgraded by two levels for very serious imprecision: low number of events (total number of events &lt; 300) and data based on one small RCT.<br/><sup>4</sup>Evidence downgraded by one level for serious imprecision: low number of events (total number of events &lt; 300).<br/><sup>5</sup>Evidence downgraded by one level for serious risk of bias: all studies considered as at unclear risk of bias for at least one domain.<br/><sup>6</sup>Evidence downgraded by two levels for serious inconsistency (I<sup>2</sup> = 87%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to stimulation protocol).<br/><sup>7</sup>Evidence downgraded by two levels for very serious imprecision: low number of events (total number of events &lt; 300) and data based on two RCTs, and 95% CI includes both appreciable benefit and harm.<br/><sup>8</sup>Evidence downgraded by one level for serious imprecision: low number of events (total number of events &lt; 300), and 95% CI includes both appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006105-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006105-sec-0009"></div> <section id="CD006105-sec-0010"> <h3 class="title" id="CD006105-sec-0010">Description of the condition</h3> <p>Polycystic ovary syndrome (PCOS) is a disorder characterised by chronic anovulation (failure or absence of ovulation) and hyperandrogenism (excessive production of male hormones in women) and is associated with irregular menstrual cycles, infertility, hirsutism, and acne (<a href="./references#CD006105-bbs2-0056" title="SperoffL , GlassRH , KaseNG . Anovulation and polycystic ovary [Anovulação e o ovário policístico]. In: Clinical Gynecology, Endocrinology and Infertility. 5th edition. São Paulo: Manole, 1995:477-502.">Speroff 1995</a>). This condition is the most common endocrine disorder in women, affecting approximately 5% to 10% of all women of reproductive age (<a href="./references#CD006105-bbs2-0043" title="FrankS . Polycystic ovary syndrome. New England Journal of Medicine1995;333:853-61.">Frank 1995</a>; <a href="./references#CD006105-bbs2-0048" title="KnochenhauerES , KeyTJ , Kahsar-MillerM , WaggonerW , BootsLR , AzzizR . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism1998;83:3078-82.">Knochenhauer 1998</a>). </p> <p>PCOS is a heterogenous condition, from a clinical as well as from a biochemical perspective. According to the recommendations proposed by an international consensus group (<a href="./references#CD006105-bbs2-0042" title="Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">ESHRE/ASRM 2003</a>), the diagnosis of PCOS is made when at least two of the following criteria are met: </p> <p> <ol id="CD006105-list-0001"> <li> <p>oligo‐ or anovulation (infrequent or no ovulation);</p> </li> <li> <p>clinical or biochemical signs of hyperandrogenism, or both;</p> </li> <li> <p>polycystic ovaries on ultrasound.</p> </li> </ol> </p> <p>Other causes of hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen‐secreting tumours) were excluded. </p> <p>Although the primary aetiology of PCOS is unknown (<a href="./references#CD006105-bbs2-0036" title="BalenA . The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2004;18:685-6.">Balen 2004</a>), insulin resistance with compensatory hyperinsulinaemia is a prominent feature of the syndrome and seems to play an important physiopathological role in hyperandrogenism, in both lean and obese women with PCOS (<a href="./references#CD006105-bbs2-0040" title="DunaifA , SegalKR , FutterweitW , DobrjanskyA . Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes1989;38:1165-74.">Dunaif 1989</a>; <a href="./references#CD006105-bbs2-0059" title="TsilchorozidouT , OvertonC , ConwayGS . The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology2004;60(1):1-17.">Tsilchorozidou 2004</a>). Hyperinsulinaemia increases ovarian androgen biosynthesis, both in vivo and in vitro (<a href="./references#CD006105-bbs2-0033" title="AdashiEY , ResnickCE , D'ErcoleAJ , SvobodaME , Van WykJJ . Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocrine Review1985;6:400-20.">Adashi 1985</a>; <a href="./references#CD006105-bbs2-0037" title="BarbieriRL , MakrisA , RandallRW , DanielsG , KistnerRW , RyanKJ . Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. Journal of Clinical Endocrinology and Metabolism1986;62:904-10.">Barbieri 1986</a>), and decreases the hepatic production of sex hormone‐binding globulin (SHBG) (<a href="./references#CD006105-bbs2-0052" title="NestlerJE , PowersLP , MattDW , SteingoldKA , PlymateSR , RittmasterRS , et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism1991;72:83-9.">Nestler 1991</a>), thus leading to increased bioavailability of free androgens. </p> </section> <section id="CD006105-sec-0011"> <h3 class="title" id="CD006105-sec-0011">Description of the intervention</h3> <p>Several treatments have been used to induce ovulation and pregnancy in infertile anovulatory women with PCOS. The use of clomiphene citrate as first‐line treatment leads to modest pregnancy rates (<a href="./references#CD006105-bbs2-0038" title="BarbieriRL . Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. American Journal of Obstetrics and Gynecology2000;183:1412-8.">Barbieri 2000</a>; <a href="./references#CD006105-bbs2-0049" title="KocakM , CaliskanE , SimsirC , HaberalA . Metformin therapy improves ovulatory rates, cervical scores and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertility and Sterility2002;77:101-6.">Kocak 2002</a>; <a href="./references#CD006105-bbs2-0058" title="Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertility and Sterility2008;89(3):505-22.">Thessaloniki ESHRE/ASRM‐Sponsored PCOS 2008</a>). Based on the association between insulin resistance and anovulation in women with PCOS, insulin‐sensitising agents, such as metformin, have recently been added to the treatment protocols of these women (<a href="./references#CD006105-bbs2-0039" title="CostelloM , ShresthaB , EdenJ , SjoblomP , JohnsonN . Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD005552. [DOI: 10.1002/14651858.CD005552.pub2]">Costello 2007</a>; <a href="./references#CD006105-bbs2-0047" title="JungheimES , OdiboAO . Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents. Fertility and Sterility2010;94(7):2659-64.">Jungheim 2010</a>; <a href="./references#CD006105-bbs2-0053" title="NestlerJE , StovallD , AkhterN , IuornoMJ , JakubowiczDJ . Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertility and Sterility2002;77:209-15.">Nestler 2002</a>). </p> </section> <section id="CD006105-sec-0012"> <h3 class="title" id="CD006105-sec-0012">How the intervention might work</h3> <p>Metformin is an orally active, water‐soluble biguanide used to treat type 2 diabetes mellitus. The drug has an antihyperglycaemic effect and does not cause hypoglycaemia. It enhances insulin sensitivity both in the liver, by inhibiting hepatic glucose production, and in peripheral tissues, such as muscle cells, by increasing glucose uptake and utilisation (<a href="./references#CD006105-bbs2-0037" title="BarbieriRL , MakrisA , RandallRW , DanielsG , KistnerRW , RyanKJ . Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. Journal of Clinical Endocrinology and Metabolism1986;62:904-10.">Barbieri 1986</a>; <a href="./references#CD006105-bbs2-0041" title="DunnCJ , PetersDH . Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs1995;49:721-49.">Dunn 1995</a>; <a href="./references#CD006105-bbs2-0051" title="NardoLG , RaiR . Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecology and Endocrinology2001;15:373-80.">Nardo 2001</a>). There is a good physiological rationale for believing that suppression of insulin levels, through the use of insulin‐sensitising agents such as metformin, may be useful in women with PCOS who are undergoing in vitro fertilisation (IVF) with or without intracytoplasmic sperm injection (ICSI). Suppression of insulin levels might ameliorate the adverse effects of ovarian stimulation and improve treatment outcomes such as ovulation and pregnancy rates (<a href="./references#CD006105-bbs2-0040" title="DunaifA , SegalKR , FutterweitW , DobrjanskyA . Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes1989;38:1165-74.">Dunaif 1989</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). In addition, metformin may also act directly on ovarian thecal cells, decreasing androgen production (<a href="./references#CD006105-bbs2-0035" title="AttiaGR , RaineyWE , CarrBR . Metformin directly inhibits androgen production in human thecal cells. Fertility and Sterility2001;76:517-24.">Attia 2001</a>; <a href="./references#CD006105-bbs2-0054" title="PalombaS , FalboA , RussoT , OrioF , TolinoA , ZulloF . Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Human Reproduction2010;25(4):1005-13.">Palomba 2010</a>). </p> </section> <section id="CD006105-sec-0013"> <h3 class="title" id="CD006105-sec-0013">Why it is important to do this review</h3> <p>Due to a large cohort of antral follicles sensible to gonadotrophins in PCOS women, the risk of developing ovarian hyperstimulation syndrome (OHSS) is high in this population who are undergoing ovarian stimulation with follicle‐stimulating hormone (FSH). Ovarian hyperstimulation syndrome is a life‐threatening iatrogenic condition, and therefore one of the most important and serious complications of assisted reproductive technology (ART). Higher total FSH doses lead to a larger number of follicles and oocytes, high serum oestradiol (E2) levels, increased risk of OHSS, elevated cancellation rates, and lower conception rates (<a href="./references#CD006105-bbs2-0032" title="AboulgharMA , MansourRT . Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Human Reproduction Update2003;9:275-89.">Aboulghar 2003</a>; <a href="./references#CD006105-bbs2-0060" title="YaraliH , ZeynelogluHB . Gonadotrophin treatment in patients with polycystic ovary syndrome. Reproductive Biomedicine Online2004;8:528-37.">Yarali 2004</a>). It is therefore important to assess the effects of metformin on the clinical, biochemical, and laboratory profiles of PCOS women undergoing ART cycles. Several adequately designed trials have addressed this question (<a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006105-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006105-sec-0014"></div> <p>To determine the effectiveness and safety of metformin as a co‐treatment during IVF or ICSI in achieving pregnancy or live birth in women with PCOS. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006105-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006105-sec-0015"></div> <section id="CD006105-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006105-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) comparing metformin treatment with placebo or no treatment in women with PCOS undergoing IVF or ICSI treatment. </p> <p>We did not include non‐randomised and quasi‐randomised trials due to their high risk of bias. We considered only the first part of cross‐over trials in the meta‐analysis. </p> </section> <section id="CD006105-sec-0018"> <h4 class="title">Types of participants</h4> <p>Women of reproductive age with anovulation attributed to PCOS, with or without another cause of couple infertility, who were treated with metformin before and during an IVF or ICSI cycle were eligible. </p> <p>The aetiology of infertility leading to treatment by IVF or ICSI was defined by the individual study authors. The diagnosis of PCOS was based on the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) criteria (<a href="./references#CD006105-bbs2-0042" title="Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">ESHRE/ASRM 2003</a>). Due to the wide variation of diagnostic criteria used for PCOS, studies that used different diagnostic criteria were included in the review if the broad definition used in the study matched the ESHRE/ASRM criteria. According to the recommendations proposed by that group, the diagnosis of PCOS is made when at least two of the following criteria are met: </p> <p> <ol id="CD006105-list-0002"> <li> <p>oligo‐ or anovulation (infrequent or no ovulation);</p> </li> <li> <p>clinical or biochemical (or both) signs of hyperandrogenism;</p> </li> <li> <p>polycystic ovaries on ultrasound.</p> </li> </ol> </p> <p>Other causes of hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen‐secreting tumours) should have been excluded. </p> </section> <section id="CD006105-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Metformin versus placebo or no treatment before and during IVF or ICSI treatment.</p> </section> <section id="CD006105-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD006105-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD006105-list-0003"> <li> <p>Live birth rate (per woman), defined as a baby born after 20 weeks of gestation.</p> </li> <li> <p>Incidence of OHSS (per woman), defined according to the definition of reporting authors.</p> </li> </ol> </p> </section> <section id="CD006105-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD006105-list-0004"> <li> <p>Clinical pregnancy rate (per woman), defined as the identification of an intrauterine gestational sac on ultrasound scan. </p> </li> <li> <p>Miscarriage rate (per woman and per pregnancy), defined as the involuntary loss of a pregnancy before 20 weeks gestation. </p> </li> <li> <p>Incidence of participant‐reported side effects (especially gastrointestinal symptoms, e.g. nausea, vomiting, and diarrhoea). </p> </li> <li> <p>Number of oocytes retrieved.</p> </li> <li> <p>Total dose of FSH (in international units (IU)).</p> </li> <li> <p>Number of days of gonadotrophin treatment.</p> </li> <li> <p>Cycle cancellation rate (per woman).</p> </li> <li> <p>Serum oestradiol level (pg/mL) on the day of human chorionic gonadotrophin (hCG) trigger injection. </p> </li> <li> <p>Serum androgen level (total testosterone, sex hormone‐binding globulin (SHBG) or free‐androgen index). </p> </li> <li> <p>Fasting insulin and glucose levels.</p> </li> <li> <p>Fertilisation rate, defined as normal fertilisation with two pronuclei‐stage embryos. The fertilisation rate was defined as the number of normally fertilised oocytes divided by the number of oocytes retrieved per cycle. </p> </li> </ol> </p> </section> </section> </section> <section id="CD006105-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We sought all relevant RCTs of metformin co‐treatment (prior to and during ovarian stimulation) in women with PCOS undergoing IVF or ICSI treatment, without language restriction. Our original search was conducted in 2008, with updated searches carried out in November 2012, September 2013, October 2014, and March 2019. The searches were performed in consultation with the Cochrane Gynaecology and Fertility Group Information Specialist. </p> <section id="CD006105-sec-0024"> <h4 class="title">Electronic searches</h4> <p>In order to identify relevant studies, we developed detailed search strategies for each specific database. </p> <p>We searched the following databases:</p> <p> <ul id="CD006105-list-0005"> <li> <p>Cochrane Gynaecology and Fertility Group Specialised Register; ProCite platform, searched 13 February 2020 (<a href="./appendices#CD006105-sec-0094">Appendix 1</a>); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO); Web platform, searched 13 February 2020 (<a href="./appendices#CD006105-sec-0095">Appendix 2</a>); </p> </li> <li> <p>MEDLINE; Ovid platform, searched from 1946 to 13 February 2020 (<a href="./appendices#CD006105-sec-0096">Appendix 3</a>); </p> </li> <li> <p>Embase; Ovid platform, searched from 1980 to 13 February 2020 (<a href="./appendices#CD006105-sec-0097">Appendix 4</a>); </p> </li> <li> <p>PsycINFO; Ovid platform, searched from 1806 to 13 February 2020 (<a href="./appendices#CD006105-sec-0098">Appendix 5</a>); </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database); Web platform, searched 13 February 2020 (<a href="./appendices#CD006105-sec-0099">Appendix 6</a>). </p> </li> </ul> </p> <p>We also searched the trial registries (until 13 February 2020) for ongoing and registered trials: </p> <p> <ul id="CD006105-list-0006"> <li> <p>ISRCTN registry (<a href="http://www.controlled-trials.com" target="_blank">www.controlled-trials.com</a>); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">www.who.int/trialsearch/Default.aspx</a>). </p> </li> </ul> </p> </section> <section id="CD006105-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the citation lists of relevant publications, review articles, and included studies. We handsearched references of identified selected articles for additional relevant citations. We also contacted experts in the field for additional relevant citations. </p> </section> </section> <section id="CD006105-sec-0026"> <h3 class="title" id="CD006105-sec-0026">Data collection and analysis</h3> <p>We analysed data using Review Manager 5 (<a href="./references#CD006105-bbs2-0055" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <section id="CD006105-sec-0027"> <h4 class="title">Selection of studies</h4> <p>For the 2020 update, two review authors (LOT and MFC) independently selected trials for inclusion in the review in accordance with the aforementioned criteria. Any disagreements were settled by a third review author (CRM). </p> </section> <section id="CD006105-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (LOT and LETA) independently extracted data using forms designed according to Cochrane guidelines. We sought additional information from the authors of trials that appeared to meet the eligibility criteria but for which the methodological details were unclear. We also sought further trial data when data in the reports were presented in a form that was unsuitable for meta‐analysis. </p> <p>Differences of opinion were registered and resolved by consensus. We planned to perform a series of analyses on the results; however, these analyses were not always possible due to an insufficient number of trials reporting on a given outcome. </p> <p>We extracted the information presented in <a href="./appendices#CD006105-sec-0100">Appendix 7</a> from the included studies, which is presented in the <a href="./references#CD006105-sec-0110" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD006105-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LOT and CRM) independently assessed the risk of bias of the included studies using the tools described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006105-bbs2-0046" title="Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We assessed selection bias (random sequence generation and allocation concealment); performance bias (blinding of participants and personnel); detection bias (blinding of outcome assessment); attrition bias (completeness of outcome data); reporting bias (selective reporting); and other bias, and summarised our judgements in the 'Risk of bias' table in <a href="./references#CD006105-sec-0110" title="">Characteristics of included studies</a>. Any disagreements were resolved by discussion. We incorporated the 'Risk of bias' assessment into the interpretation of review findings by means of sensitivity analyses. </p> </section> <section id="CD006105-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we expressed the results for each study as risk ratios (RR) with 95% confidence intervals (CIs). For continuous data, we measured the mean post‐treatment intervention values and standard deviations for each group and calculated mean differences (MDs) with 95% CIs. If similar outcomes were reported using different scales, we calculated the standardised mean differences (SMDs) with 95% CIs. </p> </section> <section id="CD006105-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed the primary outcomes (live birth rate and OHSS), clinical pregnancy rate, and cycle cancellation rate outcomes per woman. We expressed miscarriage rate per woman as well as per pregnancy. Some of the included studies reported our primary outcomes using other units of analysis (e.g. per cycle, per embryo transfer). These data were not included in the review because they were not randomised comparisons, but applied only to selected subsets of participants, such as those who underwent repeated cycles or those who underwent embryo transfer. </p> <p>We reported and pooled the review outcomes 'number of gonadotrophin units used' and 'number of days of gonadotrophin treatment', because all women underwent one treatment cycle. For studies that performed more than one cycle per woman, only the data from the first cycle were included in the meta‐analyses. </p> </section> <section id="CD006105-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>To the greatest degree possible, we analysed data on an intention‐to‐treat (ITT) basis and made attempts to obtain missing data from the original trials. When this information was not available, we performed the analysis using the original number of women randomised. </p> </section> <section id="CD006105-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity using the I<sup>2</sup> statistic, interpreting I<sup>2</sup> &gt; 50% as being indicative of substantial heterogeneity amongst studies (<a href="./references#CD006105-bbs2-0046" title="Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). </p> </section> <section id="CD006105-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by undertaking a comprehensive search for eligible studies and by paying attention to data duplication. We planned to use a funnel plot to explore the possibility of publication bias if sufficient studies (10 or more) were found for either of the primary outcomes. </p> </section> <section id="CD006105-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We combined data for meta‐analysis using Review Manager 5 to perform all the statistical analyses (<a href="./references#CD006105-bbs2-0055" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>We employed RR with 95% CI as the measure of effect for each dichotomous outcome using the Mantel‐Haenszel method, and reported continuous outcome differences between groups as MD with 95% CI. We used a random‐effects model in the analysis. </p> </section> <section id="CD006105-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed a stratified meta‐analysis according to the type of stimulation protocol (long gonadotrophin‐releasing hormone (GnRH)‐agonist or short GnRH‐antagonist) for all outcomes that presented different types of stimulation protocol used. This stratification was added in the 2014 update of the review, to examine any possible difference in effect related to the type of stimulation. </p> <p>We planned that if there was a clinically important difference in drug regimen (outside of normal clinical practice) amongst studies, we would examine the possible effects by performing subgroup analyses. </p> </section> <section id="CD006105-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding eligibility and analysis. We considered whether the review conclusions would have differed if: </p> <p> <ol id="CD006105-list-0007"> <li> <p>eligibility was restricted to studies without high risk of bias (high risk of bias in sequence generation, allocation concealment, or blinding method, or any substantial methodological or clinical characteristic); </p> </li> <li> <p>a fixed‐effect model had been adopted;</p> </li> <li> <p>the summary effect measure had been odds ratio rather than risk ratio.</p> </li> </ol> </p> </section> <section id="CD006105-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We generated a 'Summary of findings' table using GRADEpro GDT software and Cochrane methods (<a href="./references#CD006105-bbs2-0044" title="GRADEpro GDT. Version accessed 7 February 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD006105-bbs2-0046" title="Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). This table evaluates the overall quality of the body of evidence for the main review outcomes (live birth rate, OHSS, clinical pregnancy rate, miscarriage, side effects) using GRADE criteria (study limitations, i.e. risk of bias, consistency of effect, imprecision, indirectness, and publication bias). Judgements regarding evidence quality (high, moderate, low, or very low) were justified, documented, and incorporated into the reporting of results for each outcome. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006105-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006105-sec-0039"></div> <section id="CD006105-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD006105-sec-0110" title="">Characteristics of included studies</a> and <a href="./references#CD006105-sec-0111" title="">Characteristics of excluded studies</a>. </p> <section id="CD006105-sec-0041"> <h4 class="title">Results of the search</h4> <p>The 2020 search retrieved 156 citations (up to 13 February 2020). We identified 13 additional records through other sources. After title and abstract screening, we selected 12 citations for full‐text reading, of which we excluded seven studies. One study is awaiting classification (<a href="./references#CD006105-bbs2-0031" title="SunD , YaoG , WuL , WangJ , ZhaoZ , ZhaiJ . The effect of metformin on pregnancy outcome, endometrial receptivity &amp; MIRNAs in endometrium of patients with PCOS undergoing IVF/ICSI. Fertility and sterility2016;106(3):e260. [CN-01200009]">Sun 2016</a>). Thirteen studies matched the selection criteria and were included in the review (nine from the previous version plus four new studies) (see <a href="#CD006105-fig-0001">Figure 1</a> for details of the study selection process). There were five duplicate publications: <a href="./references#CD006105-bbs2-0026" title="StadtmauerL , RiehlR , TomaS , TalbertL . Use of metformin in patients with PCOS undergoing IVF-ET improves outcomes. International Journal of Gynecology and Obstetrics2000;70:B41. StadtmauerLA , RiehlRM , TomaSK , HuangS , BarkerS , TalbertLM . Metformin treatment of patients with polycystic ovarian syndrome undergoing IVF increases the number of mature oocytes, the fertilization rate and the number of embryos with changes in the levels of insulin-like growth factor. Fertility and Sterility1999;72 Suppl 1(3):12. ">Stadtmauer 1999</a> and Stadtmauer 2000, the latter being a continuation of the former; Visnova 2002 and <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>, one in English and the other in Czech; Kjotrod 2003a, <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>, and Kjotrod 2008a, all generated from the same trial; and Cheraghi 2013, Cheraghi 2014, and <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>, all generated from the same trial. In the 2014 version of the review, Tang 2010 was assessed as a study awaiting classification; the author answered and clarified that this study was part of another included study, <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>. </p> <div class="figure" id="CD006105-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006105-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We included four new studies in this 2020 review update (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>). Nine studies were included in 2014. Therefore 13 studies in total met the inclusion criteria and were included in the review (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). We emailed the authors of the newly included studies to obtain more details on study characteristics and methodological quality that were unclear in the published article. Four author groups answered our queries (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). See <a href="./references#CD006105-sec-0110" title="">Characteristics of included studies</a> and <a href="./references#CD006105-sec-0111" title="">Characteristics of excluded studies</a>. All trials reported that only one cycle per participant was permitted, with the exception of <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a> (a cross‐over trial). </p> </section> <section id="CD006105-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD006105-sec-0043"> <h5 class="title">Study design and setting</h5> <p>We included 13 parallel‐design RCTs and one cross‐over trial in the review. A total of 1132 participants were randomised. </p> <p> <ul id="CD006105-list-0008"> <li> <p>Ten studies were prospective, randomised, double‐blind, placebo‐controlled trials (metformin versus placebo) (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </li> <li> <p>One study was a prospective, open‐label, randomised, placebo‐controlled, cross‐over trial (<a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>). Only data from the pre‐cross‐over phase of this study were considered for meta‐analysis. </p> </li> <li> <p>Two studies were prospective RCTs (metformin versus no treatment) (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </li> </ul> </p> </section> <section id="CD006105-sec-0044"> <h5 class="title">Participants</h5> <p>All participants were women undergoing IVF or ICSI treatments. A total of 1132 women were randomised: 562 to placebo or no treatment, and 570 to metformin. </p> <section id="CD006105-sec-0045"> <h6 class="title">Baseline characteristics of the studied groups</h6> <p>Twelve studies met the Rotterdam criteria, <a href="./references#CD006105-bbs2-0042" title="Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">ESHRE/ASRM 2003</a>, for PCOS (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). One study did not meet the Rotterdam criteria because other causes for hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen‐secretin tumours) were not reported as excluded (<a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> <p>Seven studies did not report the causes of infertility (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> <p>Nine studies provided full baseline characteristics of the women in both groups (age, body mass index (BMI), duration of infertility, previously used treatment) (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). In two studies the baseline characteristics of women were incomplete (only age and BMI provided) (<a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). Two studies did not report any baseline characteristics of participating women (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>). Three studies did not report exclusion criteria (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>). </p> </section> </section> <section id="CD006105-sec-0046"> <h5 class="title">Interventions</h5> <p>Two studies started metformin on the day of ovarian stimulation with FSH (<a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). The remaining 11 studies used metformin before and during ovarian stimulation for IVF or ICSI treatment. Metformin commencement varied from 16 weeks before (earliest) to the first day (latest) of GnRH‐agonist administration in the studies reporting metformin use before FSH treatment and continued at least until the day of the hCG trigger. </p> <p>Metformin was used 500 mg twice daily in three studies (<a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>); 850 mg twice daily in two studies (<a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>); and 500 mg three times daily in five studies (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>). <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> used metformin 850 mg twice daily (BMI &lt; 28 kg/m<sup>2</sup>) or three times daily (BMI &gt;= 28 kg/m<sup>2</sup>); <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a> used metformin 850 mg three times daily; and <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a> gradually increased the dose of metformin from 500 mg to 2 g per day during the first week of treatment. </p> <p>Eight of the 13 included studies used long protocol GnRH‐agonist with recombinant FSH (rec‐FSH), whilst three studies used short protocol GnRH‐antagonist with rec‐FSH (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>). Only <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a> used either rec‐FSH or highly purified FSH (hp‐FSH), and only <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a> used HMG (hp‐ human menopausal gonadotrophin) in long protocol GnRH‐agonist ovarian stimulation protocol. </p> <p>The method of oocyte fertilisation varied amongst the trials and included IVF alone (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>), ICSI alone (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>), or a combination of IVF and ICSI, depending on the cause of infertility (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). Two trials did not report whether IVF or ICSI was performed (<a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> <p>A maximum of two embryos were transferred on day two after oocyte retrieval by <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a> and on day three by <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a> and <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>. <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> transferred up to two embryos, but on day three or day five (blastocyst stage). A maximum of three embryos were transferred on day two by <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a> and on day three by <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>. <a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a> and <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a> transferred up to two embryos on day two or three. <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a> transferred two to four embryos on day three. <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a> transferred a maximum of four embryos on day two or day three. <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a> transferred a maximum of two embryos on day two, three, or five (blastocyst stage). <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a> and <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a> did not report the number of embryos transferred. Three studies reported performing embryo transfer under ultrasound guidance (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> <p>The type of luteal phase support also varied amongst the trials and included vaginal progesterone capsules (Progestan 200 mg three times daily) (<a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>), vaginal progesterone gel (Crinone 90 mg ‐ 8% daily) (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>), vaginal progesterone pessaries (Cyclogest 400 mg daily) (<a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>), intramuscular progesterone (25 mg, 50 mg, or 100 mg daily) (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>), and progesterone, with type and dose selected by the physician (<a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>). Three studies did not report what type of medication was used for luteal phase support (<a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> <p><a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> performed selective assisted hatching with laser when: the woman was over 35 years of age; the zona pellucida was considered thick; an abnormally shaped zona was present; or excessive embryo fragmentation or slowly developing embryos were noted. We considered this procedure to be substantially different from that used in the other trials. </p> </section> <section id="CD006105-sec-0047"> <h5 class="title">Outcomes</h5> <section id="CD006105-sec-0048"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD006105-list-0009"> <li> <p>7/13 studies reported live birth rate (per woman) (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </li> <li> <p>11/13 studies reported OHSS (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </li> </ul> </p> <p>The publication by <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> did not provide the live birth rate; we obtained this information after contacting the author by email. </p> </section> <section id="CD006105-sec-0049"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD006105-list-0010"> <li> <p>12/13 studies reported clinical pregnancy rate (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </li> <li> <p>8/13 studies reported miscarriage rate (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). Miscarriage was defined as the involuntary loss of a pregnancy before 20 weeks gestation. </p> </li> <li> <p>8/13 studies reported participant‐reported side effects (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </li> <li> <p>10/13 studies reported the number of oocytes retrieved, total dose of FSH per woman (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </li> <li> <p>9/13 studies reported the number of days of gonadotrophin treatment per woman (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </li> <li> <p>Only <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a> did not report secondary outcomes, and we were unsuccessful in contacting the author. </p> </li> <li> <p>8/13 studies reported cancellation rates (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </li> <li> <p>6/13 studies reported serum oestradiol level on the day of hCG (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </li> <li> <p>3/13 studies reported fertilisation rate (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </li> <li> <p>Of the four newly included studies (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>), only <a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a> reported all the main clinical outcomes (live birth rate, incidence of OHSS, clinical pregnancy rate, miscarriage rate, and side effects). We contacted the authors by email to obtain more information about the outcomes not reported; however, only <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a> answered with clarification. </p> </li> </ul> </p> </section> </section> </section> <section id="CD006105-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded 17 studies after full‐text review. The reasons for exclusion were as follows:</p> <p> <ul id="CD006105-list-0011"> <li> <p><a href="./references#CD006105-bbs2-0020" title="HeY , LuY , ZhuQ , WangY , LindheimSR , QiJ , et al. Influence of metabolic syndrome on female fertility and in vitro fertilization outcomes in PCOS women. American journal of obstetrics and gynecology2019;221(2):138. ">He 2019</a> (retrospective data analysis); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0014" title="AbdalmageedOS , FarghalyTA , AbdelaleemAA , AbdelmagiedAE , AliMK , AbbasAM . Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Controlled Trial. Reproductive Sciences (Thousand Oaks, Calif.)2019;26(10):1336-42.. [PMID: 29576001]AbdalmageedOS , FarghalyTA , IsmailAM , HurdWW . Impact of metformin on in vitro fertilization outcomes in overweight and obese polycystic ovary syndrome women: a prospective cohort Study. Fertility and Sterility2016;106(3 Suppl):e262. ">Abdalmageed 2019</a> (not an RCT); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0015" title="AkbariAF . Evaluating the effect of the metformin treatment on ICSI in infertile PCOS women. Iranian Journal of Reproductive Medicine2010;8:8. ">Akbari 2010</a> (abstract of a congress oral presentation with data not available; we contacted the authors but received no response); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0016" title="DemirolA , SariT , GirginB , KentE , GurganT . The effect of metformin treatment on the ICSI cycle outcome in PCOS patients. Human Reproduction2006;21(Suppl 1):i88. ">Demirol 2006</a> (not an RCT); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0017" title="EgbasePE , Al SharhanM , BuzaberM , GrudzinskasJG . Prospective randomised study of metformin in IVF and embryo transfer treatment cycles in obese patients with polycystic ovarian syndrome. Human Reproduction2001;16 Suppl 1:202. ">Egbase 2001</a> (data irregularities); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0018" title="GeusaS , StanzianoA , CausioF , PansiniN , SarcinaE . The efficacy of insulin-sensitizing agent (metformin) in PCOS and insulin resistance patients undergoing IVF treatment. Human Reproduction2002;17 Suppl:115. ">Geusa 2002</a> (data irregularities); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0019" title="GhasemiN , JahaninejadT , SheidaE , AflatoonianA . Effectiveness of Metformin in treatment of infertility and recurrent pregnancy loss in polycystic ovarian syndrome. Iranian journal of reproductive medicine2012;10:8. ">Ghasemi 2012</a> (women had a history of unexplained recurrent pregnancy loss and PCOS); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0021" title="ImmediataV , RomualdiD , De CiccoS , TagliaferriV , Di FlorioC , CirellaE , et al. Metformin versus myoinositol: which one is better in obese PCOS patients - a crossover study on clinical, endocrine and metabolic effects. Human Reproduction (Oxford, England)2014;29:i334. ">Immediata 2014</a> (different interventions); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0022" title="KahramanS , VanliogluF , YakinK , CengizS , KarlikayaG . A comparative trial of metformin and oral contraceptive pretreatment in patients with polycystic ovary syndrome undergoing ICSI for severe male factor infertility. Fertility and Sterility2001;76 Suppl 1(3):67. ">Kahraman 2001</a> (control group treated with oral contraceptives rather than placebo or no treatment); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0023" title="PalombaS , FalboA , Di CelloA , CappielloF , TolinoA , ZulloF . Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertility and sterility2011;96(5):1128-33. [PMID: 21917254]">Palomba 2011a</a> (women were poor responders); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0024" title="PourmatroudE , MohamadJafariR . Comparison of metformin and simvastatin administration in women with polycystic ovary syndrome before intracytoplasmic sperm injection cycle; a prospective, randomized, clinical trial. Human Reproduction (Oxford, England)2014;29:i334-5. [DOI: 10.1093/humrep/29.Supplement_1.1] [CN-01473786]PourmatroudE , MohammadjafariR , RoozitalabM . Comparison of Metformin and Simvastatin Administration in Women With Polycystic Ovary Syndrome Before Intra-Cytoplasmic Sperm Injection Cycle: a Prospective, Randomized, Clinical Trial Study. Iranian Red Crescent medical journal2015;17(12):e20082. [PMID: 26756007]PourmatroudE , Mohammad JafariR . Two protocols for pretreatment in women with polycystic ovary syndrome before intracytoplasmic sperm injection cycle; a prospective, randomized, clinical trial. Iranian journal of reproductive medicine2014;12(6 Suppl 1):4-5. [CN-01107870]">Pourmatroud 2015</a> (different interventions); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0025" title="SchachterM , RazielA , StrassburgerD , RotemC , Ron-ElR , FriedlerS . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2007;88(1):227-30. ">Schachter 2007</a> (women specifically undergoing ICSI were not randomised separately); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0026" title="StadtmauerL , RiehlR , TomaS , TalbertL . Use of metformin in patients with PCOS undergoing IVF-ET improves outcomes. International Journal of Gynecology and Obstetrics2000;70:B41. StadtmauerLA , RiehlRM , TomaSK , HuangS , BarkerS , TalbertLM . Metformin treatment of patients with polycystic ovarian syndrome undergoing IVF increases the number of mature oocytes, the fertilization rate and the number of embryos with changes in the levels of insulin-like growth factor. Fertility and Sterility1999;72 Suppl 1(3):12. ">Stadtmauer 1999</a> (women acted as their own control); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0027" title="StadtmauerLA , TomaSK , RiehlRM , TalbertLM . Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertility and Sterility2001;75(3):505-9. ">Stadtmauer 2001</a> (retrospective data analysis); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0028" title="StadtmauerLA , WongBC , OehningerS . Impact of metformin therapy on ovarian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing in-vitro fertilization. Reproductive Biomedicine Online2002;5(2):112-6. ">Stadtmauer 2002</a> (not an RCT); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0029" title="SwantonA , LightenA , GranneI , McVeighE , LaveryS , TrewG , et al. Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. Human Reproduction (Oxford, England)2011;26(8):2178-84. [DOI: 10.1093/humrep/der120] [CN-01261056]">Swanton 2011</a> (women with ovaries of polycystic morphology (PCO) on ultrasound were included, not PCOS women); </p> </li> <li> <p><a href="./references#CD006105-bbs2-0030" title="TasdemirS , FiciciogluC , YaltiS , GurbuzB , BasaranT , YildirimG . The effect of metformin treatment to ovarian response in cases with PCOS. Archives of Gynecology and Obstetrics2004;269(2):121-4. [PMID: 12764624]">Tasdemir 2004</a> (women undergoing ovulation induction cycles, not IVF or ICSI cycles). </p> </li> </ul> </p> </section> </section> <section id="CD006105-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD006105-fig-0002">Figure 2</a> and <a href="#CD006105-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006105-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006105-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006105-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006105-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006105-sec-0052"> <h4 class="title">Allocation</h4> <section id="CD006105-sec-0053"> <h5 class="title">Random sequence generation</h5> <p>Eight trials reported acceptable methods of sequence generation and were judged as being at low risk of bias for this domain (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). Six studies used computer randomisation (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>), and two a random numbers table (<a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). The other five studies did not report what methods were used for sequence generation and were classified as being at unclear risk of bias for this domain (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> </section> <section id="CD006105-sec-0054"> <h5 class="title">Allocation concealment</h5> <p>Seven studies were at low risk of bias for allocation concealment because they used either sequentially numbered, sealed, opaque envelopes (<a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>), or codes kept by a third party such as the pharmacy department, <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>, or a trial office (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). Five studies did not report allocation concealment method used and were judged as having an unclear risk of bias (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). One study reported using sealed envelopes, but it was unclear whether or not they were opaque, even after contacting the authors via email, thus it was also classified as having an unclear risk of bias (<a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>). </p> </section> </section> <section id="CD006105-sec-0055"> <h4 class="title">Blinding</h4> <p>We did not consider that blinding was likely to influence findings for the main clinical review outcomes (live birth rate, clinical pregnancy rate, and incidence of OHSS). However, blinding status could potentially affect findings for side effects. </p> <section id="CD006105-sec-0056"> <h5 class="title">For performance bias:</h5> <p>Eight studies reported double‐blinding and were classified as being at low risk of bias for this domain (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). Three studies were open‐label comparisons (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>), and one was single‐blind (<a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>), and were therefore classified as being at high risk of bias. One study was described as double‐blind (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>); however, the blinding method used was not reported, therefore we judged this study to be at unclear risk of performance bias. </p> </section> <section id="CD006105-sec-0057"> <h5 class="title">For detection bias:</h5> <p>Only one study reported blinding of outcome assessment (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>), and was classified as being at low risk of bias for this domain. Eight studies did not report blinding of assessors and were therefore assessed as being at unclear risk of detection bias (<a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). Three studies were open‐label comparisons (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>), and one was single‐blind (<a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>); we classified these studies as being at high risk of detection bias. </p> </section> </section> <section id="CD006105-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>We judged 10 studies to be at low risk of bias because they analysed their data on an ITT basis (trial participants were analysed in the groups to which they had been randomised; all participants were included as there were no withdrawals) (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> <p>One study did not report the reasons for withdrawals and was judged to be at unclear risk of bias for this domain (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>). </p> <p>One study did not perform ITT analysis and was therefore classified being at unclear risk of attrition bias (<a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>). </p> <p>One study conducted available‐case analyses (trial participants were analysed in the groups to which they had been randomised, and only participants who completed the trials were included) and was judged to be at high risk of bias for this domain (<a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>). </p> </section> <section id="CD006105-sec-0059"> <h4 class="title">Selective reporting</h4> <p>Seven studies reported live birth and OHSS rates (the primary outcomes of this review) and were therefore classified as being at low risk of bias (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> <p>We judged five studies to be at unclear risk for reporting bias because they failed to report at least one of the following outcomes: live birth or OHSS rates (the primary outcomes of this review) (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> <p><a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a> did not report either of the primary outcomes of this review and was classified as being at high risk of bias. </p> </section> <section id="CD006105-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies did not report the causes of infertility and were thus deemed as at unclear risk of other bias (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). </p> <p>We rated <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a> as being at high risk of bias for this domain due to a data discrepancy. We attempted to contact the authors for clarification, without success. </p> <p>We assessed the remaining eight studies as being at low risk of other bias (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </section> </section> <section id="CD006105-sec-0061"> <h3 class="title" id="CD006105-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD006105-tbl-0001"><b>Summary of findings 1</b> Metformin compared to placebo or no treatment in women with polycystic ovary syndrome</a> </p> <section id="CD006105-sec-0062"> <h4 class="title">1. Comparison of metformin versus placebo or no treatment</h4> <section id="CD006105-sec-0063"> <h5 class="title">Primary outcomes</h5> <section id="CD006105-sec-0064"> <h6 class="title">1.1 Live birth rate (per woman)</h6> <p>Seven studies reported live birth (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). We detected substantial heterogeneity (I<sup>2</sup> = 77%; P &lt; 0.001), which may be explained by the difference in effect of the interventions between the study protocol subgroups (test for subgroup difference: P = 0.001, I<sup>2</sup> = 90.5%). We therefore analysed the results per study protocol subgroup, that is studies that used a long protocol GnRH‐agonist and those using a short protocol GnRH‐antagonist. </p> <p>Six studies used a long protocol GnRH‐agonist (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). Pooled evidence from these six studies showed that we are uncertain of the effect of metformin on live birth rate per woman when compared with placebo/no treatment (risk ratio (RR) 1.30, 95% confidence interval (CI) 0.94 to 1.79; 6 RCTs; 651 women; I<sup>2</sup> = 47%; low‐quality evidence; <a href="http://1.0.0.1/" target="_blank">Analysis 1.1</a>; <a href="#CD006105-fig-0004">Figure 4</a>). We estimated that for a woman with a 28% chance of achieving a live birth using placebo or no treatment, the chance using metformin would be between 27% and 51%. </p> <div class="figure" id="CD006105-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate per woman." data-id="CD006105-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate per woman. </p> </div> </div> </div> <p>We conducted a post hoc sensitivity analysis due to a data discrepancy (suspected risk of bias) in one of the studies (<a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>). According to the study publication, in both the metformin group and placebo/no treatment group the clinical pregnancy rate (26/60 and 24/60) was lower than the live birth rate (29/60 and 27/60). Our attempts to contact the first author have to date received no response. Sensitivity analysis excluding this study yielded an RR of 1.38 (95% CI 0.91 to 2.10; I<sup>2</sup> = 52%) for live birth, which did not substantially change our findings (<a href="#CD006105-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD006105-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Sensitivity analysis by excluding Palomba 2011 due to a data discrepancy (suspected risk of bias)." data-id="CD006105-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sensitivity analysis by excluding Palomba 2011 due to a data discrepancy (suspected risk of bias). </p> </div> </div> </div> <p>Only one study used a short protocol GnRH‐antagonist and reported live birth rate (<a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>). Metformin may reduce live birth rate compared with placebo/no treatment (RR 0.48, 95% CI 0.29 to 0.79; 1 RCT; 153 women; low‐quality evidence; <a href="./references#CD006105-fig-0011" title="">Analysis 1.1</a>). This suggests that if the chance for live birth following placebo/no treatment is 43%, the chance following metformin would be between 13% and 34%. </p> <p>We also performed sensitivity analysis using a fixed‐effect model and observed a difference in results for this outcome when a long protocol GnRH agonist was used (RR 1.30, 95% CI 1.04 to 1.62; 6 RCTs; 651 women; I<sup>2</sup> = 47%) which could be due to the heterogeneity observed. It is known that when heterogeneity is present, CIs are wider when a random‐effects method is used rather than a fixed‐effect method, and the estimated effect is more conservative (<a href="./references#CD006105-bbs2-0050" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV . Summarizing study characteristics and preparing for synthesis. HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors(s). version 6.1 edition. Cochrane, 2020.">McKenzie 2020</a>). </p> <p>Sensitivity analysis using odds ratio rather than RR did not lead to a difference in results. </p> </section> <section id="CD006105-sec-0065"> <h6 class="title">1.2 Incidence of OHSS</h6> <p>When we combined data from 11 studies (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>), we found that metformin may reduce the incidence of OHSS when compared with placebo/no treatment (RR 0.46, 95% CI 0.29 to 0.72; 11 RCTs; 1091 women; I<sup>2</sup> = 38%; low‐quality evidence; <a href="./references#CD006105-fig-0012" title="">Analysis 1.2</a>; <a href="#CD006105-fig-0006">Figure 6</a>). This suggests that for a woman with a 20% risk of OHSS without metformin, the corresponding risk using metformin would be between 6% and 14%. Sensitivity analysis including only studies with a low risk of bias resulted in an RR of 0.48 (95% CI 0.25 to 0.91; 6 RCTs; 696 women; I<sup>2</sup> = 51%; <a href="#CD006105-fig-0007">Figure 7</a>) (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>), which did not influence the findings. </p> <div class="figure" id="CD006105-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman." data-id="CD006105-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman. </p> </div> </div> </div> <div class="figure" id="CD006105-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Sensitivity analysis including only studies with low risk of bias (An 2014; Jacob 2016; Kjotrod 2004; Kjotrod 2011; Palomba 2011; Tang 2006)." data-id="CD006105-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sensitivity analysis including only studies with low risk of bias (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </div> </div> </div> <p>The funnel plot showed asymmetry, which may have reflected publication bias or smaller studies of lower methodological quality, hence producing a large intervention effect estimate (i.e. <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>), or chance (<a href="#CD006105-fig-0008">Figure 8</a>). Sensitivity analysis adopting a fixed‐effect model and summary effect measure risk ratio did not lead to a change in the results. </p> <div class="figure" id="CD006105-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman." data-id="CD006105-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman. </p> </div> </div> </div> </section> </section> <section id="CD006105-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD006105-sec-0067"> <h6 class="title">1.3 Clinical pregnancy rate (per woman)</h6> <p>We included data from 12 studies for this outcome (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). The data were pooled only within the study protocol subgroups due to substantial heterogeneity observed (I<sup>2</sup> = 57%; P = 0.008), although the detected heterogeneity was not explained by the difference in effect of the interventions between the study protocol subgroups (test for subgroup difference: P = 0.97, I<sup>2</sup> = 0%). This outcome was analysed according to the two subgroups, that is studies using a long protocol GnRH‐agonist and those using a short protocol GnRH‐antagonist. </p> <p>Using a long protocol GnRH‐agonist (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>), metformin may increase the clinical pregnancy rate per woman compared with placebo/no treatment (RR 1.32, 95% CI 1.08 to 1.63; 10 studies; 915 women; I<sup>2</sup> = 13%; low‐quality evidence; <a href="./references#CD006105-fig-0013" title="">Analysis 1.3</a>; <a href="#CD006105-fig-0009">Figure 9</a>). This suggests that for a woman with a 28% chance of achieving a clinical pregnancy using a long protocol GnRH‐agonist with placebo/no treatment, the chance with metformin would be between 30% and 45%. </p> <div class="figure" id="CD006105-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman." data-id="CD006105-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman. </p> </div> </div> </div> <p>As noted above, we conducted a post hoc sensitivity analysis due to a data discrepancy in one of the studies (<a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>). Sensitivity analysis excluding this study yielded an RR of 1.39 (95% CI 1.10 to 1.76; I<sup>2</sup> = 15%) for pregnancy, which did not substantially change our findings. </p> <p>Using a short protocol GnRH‐antagonist (<a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>), we are uncertain of the effect of metformin on clinical pregnancy rate per woman compared with placebo/no treatment (RR 1.38, 95% CI 0.21 to 9.14; 2 studies; 177 women; I<sup>2</sup> = 87%; very low‐quality evidence; <a href="./references#CD006105-fig-0013" title="">Analysis 1.3</a>). Most of the heterogeneity appeared to be due to <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>, as this was the only study in which clinical pregnancy rates were higher in the placebo/no treatment group compared with the metformin group. </p> <p>The funnel plot showed asymmetry, which in this case may be due to publication bias or smaller studies of lower methodological quality, hence producing a larger intervention effect estimate (i.e. <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>), or chance (<a href="#CD006105-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD006105-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman." data-id="CD006105-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman. </p> </div> </div> </div> </section> <section id="CD006105-sec-0068"> <h6 class="title">1.4 Miscarriage rate (per woman)</h6> <p>We included eight studies in this analysis (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). We are uncertain of the effect of metformin on miscarriage rate per woman when compared with placebo/no treatment (RR 0.86, 95% CI 0.56 to 1.32; 8 RCTs; 821 women; I<sup>2</sup> = 0%; low‐quality evidence; <a href="./references#CD006105-fig-0014" title="">Analysis 1.4</a>). This suggests that if the risk of miscarriage with placebo/no treatment is 11%, the risk with metformin would be between 6% and 14%. </p> </section> <section id="CD006105-sec-0069"> <h6 class="title">1.5 Miscarriage rate (per pregnancy)</h6> <p>We included eight studies in this analysis (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). We are uncertain of the effect of metformin on miscarriage rate per pregnant woman when compared with placebo/no treatment (RR 0.81, 95% CI 0.51 to 1.31; 8 RCTs; 312 women; I<sup>2</sup> = 23%; low‐quality evidence; <a href="./references#CD006105-fig-0015" title="">Analysis 1.5</a>). </p> </section> <section id="CD006105-sec-0070"> <h6 class="title">1.6 Incidence of participant‐reported side effects</h6> <p>Eight studies reported this outcome (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0006" title="KimC , JeungY , MoonJ , KangB . Effect of metformin treatment on intrafollicular cytokines, ovarian response to gonadotropin and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertility and Sterility2016;106(3 Suppl):e259-60. [CTG: NCT03086005] [CN-01200008]">Kim 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> <p>Metformin (116/375, 30.9%) may result in an increase in side effects compared with placebo/no treatment (33/373, 8.8%) (RR 3.35, 95% CI 2.34 to 4.79; 8 RCTs; 748 women; I<sup>2</sup> = 0%; low‐quality evidence; <a href="./references#CD006105-fig-0016" title="">Analysis 1.6</a>). This suggests that if the risk of side effects with placebo/no treatment is 9%, the risk with metformin would be between 21% and 42%. </p> <p><a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a> and <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a> reported that the most frequent side effects associated with metformin were gastrointestinal and included nausea, vomiting, diarrhoea, abdominal discomfort or pain. </p> </section> <section id="CD006105-sec-0071"> <h6 class="title">1.7 Number of oocytes retrieved per woman</h6> <p>We included 11 studies in this analysis (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). The mean number of oocytes retrieved per woman did not differ between groups (mean difference (MD) 0.03, 95% CI −1.42 to 1.48; 11 RCTs; 890 women; I<sup>2</sup> = 56%; <a href="./references#CD006105-fig-0017" title="">Analysis 1.7</a>). </p> <p>The 11 studies were subdivided into two subgroups: those using a long protocol GnRH‐agonist and those using short protocol GnRH‐antagonist. <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a> and <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> used a short protocol GnRH‐antagonist. There was no difference between the results of the two subgroups, and only one individual trial, <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>, demonstrated a significant difference in the number of oocytes collected between the two treatment groups, with fewer oocytes collected in the metformin group. </p> </section> <section id="CD006105-sec-0072"> <h6 class="title">1.8 Total dose of FSH (IU) per woman</h6> <p>We included 10 studies in this analysis (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). Due to extreme heterogeneity (I<sup>2</sup> = 96%), we did not pool data (<a href="./references#CD006105-fig-0018" title="">Analysis 1.8</a>). Most of the heterogeneity appeared to be due to <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; exclusion of this study reduced heterogeneity to I<sup>2</sup> = 43%. However, we did not identify any clear methodological difference between this study and the others. Eight of 10 studies found no evidence of a difference between groups (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </section> <section id="CD006105-sec-0073"> <h6 class="title">1.9 Mean number of days of gonadotrophin treatment</h6> <p>Nine studies reported this outcome (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). The mean number of days of gonadotrophin treatment did not differ significantly between groups (MD −0.17 days, 95% CI −0.71 to 0.37; 9 studies; 796 women; I<sup>2</sup> = 49%; <a href="./references#CD006105-fig-0019" title="">Analysis 1.9</a>). There was statistical heterogeneity in this comparison (I<sup>2</sup> = 49%), which disappeared (I<sup>2</sup> = 0%) when we excluded <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>, but we could not identify any clear methodological difference between this study and the others. </p> <p>We also analysed this outcome by subdividing studies into two subgroups: those using a long protocol GnRH‐agonist and those using short protocol GnRH‐antagonist. Seven studies used long protocol GnRH‐agonist (<a href="./references#CD006105-bbs2-0004" title="FedorcsakP , DalePO , StorengR , AbyholmT , TanboT . The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. Gynecological Endocrinology2003;17:207-14. ">Fedorcsak 2003</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>), and there were no statistically significant differences between the groups (MD −0.22 days, 95% CI −0.89 to 0.45; 7 RCTs; 603 women; I<sup>2</sup> = 62%). Two studies used short protocol GnRH‐antagonist and found no evidence of a difference between groups (MD 0.00 days, 95% CI −1.04 to 1.04; 2 RCTs; 193 women; I<sup>2</sup> = 0%) (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>). </p> </section> <section id="CD006105-sec-0074"> <h6 class="title">1.10 Cycle cancellation rate</h6> <p>We included eight studies in this analysis (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). Due to wide CI crossing the line of no effect, we could not determine if there is a difference between the metformin group (58/442, 13.1%) and the placebo/no treatment group (69/435, 15.8%) in cancellation rates (RR 0.74, 95% CI 0.43 to 1.29; 8 RCTs; 877 women; I<sup>2</sup> = 46%; <a href="./references#CD006105-fig-0020" title="">Analysis 1.10</a>). </p> <p>We also analysed this outcome according to subgroups, that is long protocol GnRH‐agonist, <a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>, and short protocol GnRH‐antagonist, <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>, finding no substantial heterogeneity between them (I<sup>2</sup> = 0%; P = 0.56). </p> </section> <section id="CD006105-sec-0075"> <h6 class="title">1.11 Serum oestradiol level (on the day of hCG): mean level per woman</h6> <p>Six studies reported this outcome (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a>; <a href="./references#CD006105-bbs2-0011" title="QublanHS , Al-KhadereiS , Abu-SalemAN , Al-ZpoonA , Al-KhateebM , Al-IbrahimN , et al. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. Journal of Obstetrics and Gynecology2009;29(7):651-5. ">Qublan 2009</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). Due to very high heterogeneity (I<sup>2</sup> = 89%) that could not be explained, we did not pool the studies. Three of the six studies reported lower serum oestradiol levels in the metformin group, whilst the other three studies found no evidence of a difference between groups (<a href="./references#CD006105-fig-0021" title="">Analysis 1.11</a>). </p> <p><a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a> reported serum oestradiol levels using multiple linear regression analysis. After adjustment for the total FSH dose and the number of follicles, metformin treatment reduced oestradiol concentration on the day of hCG administration (coefficient = −35.6, P = 0.048). </p> </section> <section id="CD006105-sec-0076"> <h6 class="title">1.12 Serum androgen levels (testosterone, SHBG, free‐androgen index)</h6> <p><a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> and <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a> reported serum androgen levels on the day of hCG. We were unable to pool these data because they were reported as median and range by <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> and as geometric measures by <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>. </p> <p><a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> found no difference in total testosterone between the metformin group (median 3.1, range 2.5 to 3.9) and the placebo/no treatment group (median 3.1, range 2.4 to 3.9, P = 0.646). <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a> reported that whilst testosterone levels did not change in the metformin group (baseline geometric mean: 2.03 nmol/L, geometric mean on the day of hCG administration: 1.97 nmol/L; P = 0.892), the placebo/no treatment group had an increase in testosterone levels (baseline geometric mean: 2.06 nmol/L, geometric mean on the day of hCG administration: 2.52 nmol/L; P = 0.040). In the metformin group, on the day of hCG administration there was a decrease in testosterone concentration (geometric mean: 1.96 versus 2.52 nmol/L; P = 0.029) and in the free‐androgen index (geometric mean: 2.43 versus 3.34; P = 0.004). See <a href="./references#CD006105-fig-0022" title="">Analysis 1.12</a>. </p> </section> <section id="CD006105-sec-0077"> <h6 class="title">1.13 Fasting insulin and glucose levels</h6> <p><a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> and <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a> reported fasting insulin and glucose levels on the day of hCG. Data could not be pooled because they were reported as glucose/insulin ratio (median and range) by <a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> and as Quantitative Insulin Sensitivity Check Index (QUICKI) by <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>. </p> <p><a href="./references#CD006105-bbs2-0009" title="OnalanG , PabuccuR , GoktolgaU , CeyhanT , BagisT , CincikM . Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertility and Sterility2005;84(3):798-801. ">Onalan 2005</a> found no difference in the glucose/insulin ratio between the metformin group (median 6; range 2.4 to 8.8) and the placebo/no treatment group (median 6; range 3 to 10, P = 0.81). <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a> found no difference in the insulin sensitivity test results (QUICKI) between baseline and the day of oocyte retrieval in either the metformin group (baseline 0.377 and 0.417 at the day of oocyte retrieval (P = 0.2)) or the placebo/no treatment group (baseline 0.386 and 0.400 at the day of oocyte retrieval (P = 0.572)). See <a href="./references#CD006105-fig-0023" title="">Analysis 1.13</a>. </p> </section> <section id="CD006105-sec-0078"> <h6 class="title">1.14 Fertilisation rate</h6> <p>Four studies reported fertilisation rate with two pronuclei‐stage embryos, but in different ways (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). We therefore pooled only <a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a> and <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>. The mean fertilisation rate did not differ between groups (MD −4.78, 95% CI −12.21 to 2.65; 2 RCTs; 225 women; I<sup>2</sup> = 19%; <a href="./references#CD006105-fig-0024" title="">Analysis 1.14</a>). </p> <p><a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a> (metformin: 57.5 ± 25.9; placebo: 56.8 ± 26.3) and <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> (metformin: 53.3 ± 25.4; placebo: 60.5 ± 22.2) reported fertilisation rate as percentage of fertilisation. </p> <p><a href="./references#CD006105-bbs2-0002" title="CheraghiE , MehranjaniMS , ShariatzadehMA , EsfahaniMH , EbrahimiZ . N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reproduction, Fertility, and Development2016;28(6):723-31. [PMID: 25482371]CheraghiE , Soleimani MehranjaniM , ShariatzadehMA , Nasr EsfahaniMH , EbrahimiZ . Co-Administration of metformin and N-Acetyl cysteine fails to improve clinical manifestations in PCOS individual undergoing ICSI. International Journal of Fertility &amp; Sterility2014;8(2):119-28. [PMID: 25083175]CheraghiE , Soleimani MehranjaniM , ShariatzadehSMA , Nasr EsfahaniMH , AlaniB . N-Acetylcysteine compared to metformin, improves the expression profile of growth differentiation factor-9 and receptor tyrosine kinase c-Kit in the oocytes of patients with polycystic ovarian syndrome. International Journal of Fertility &amp; Sterility2018;11(4):270-8. [PMID: 29043702]">Cheraghi 2018</a> reported fertilisation rate as the number of oocytes fertilised (metformin: 9.2 ± 4.5; placebo: 5.6 ± 2.2). </p> <p><a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a> reported fertilisation rate per oocyte retrieved. Metformin did not improve the overall fertilisation rate (52.9% versus 54.9%, P = 0.641) (data not shown). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006105-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006105-sec-0079"></div> <section id="CD006105-sec-0080"> <h3 class="title" id="CD006105-sec-0080">Summary of main results</h3> <section id="CD006105-sec-0081"> <h4 class="title">Reproductive outcomes</h4> <p>Due to substantial heterogeneity, we did not perform meta‐analysis on the overall (both ovarian stimulation protocols combined) data for the effect of metformin on the outcomes of live birth and clinical pregnancy rates per woman in women with PCOS undergoing IVF/ICSI treatment. </p> <p>With the use of the long protocol GnRH‐agonist ovarian stimulation, we are uncertain of the effect of metformin on live birth rate per woman when compared with placebo/no treatment (<a href="./references#CD006105-fig-0011" title="">Analysis 1.1</a>), but metformin may increase the clinical pregnancy rate per woman (<a href="./references#CD006105-fig-0013" title="">Analysis 1.3</a>). </p> <p>Using the short protocol GnRH‐antagonist ovarian stimulation, metformin may reduce live birth rate compared with placebo/no treatment (<a href="./references#CD006105-fig-0011" title="">Analysis 1.1</a>), and we are uncertain of the effect of metformin on clinical pregnancy rate per woman (<a href="./references#CD006105-fig-0013" title="">Analysis 1.3</a>). The authors of the one RCT assessing the effect of metformin on live birth rate stated that the finding of a reduced live birth rate with metformin should be viewed with caution, as this outcome was not the primary outcome for the study (i.e. the RCT was not powered for this outcome) and may represent a purely chance outcome. </p> <p>Overall, metformin may reduce the incidence of OHSS when compared with placebo/no treatment; this finding was demonstrated in the long protocol GnRH‐agonist ovarian stimulation protocol but not the short GnRH‐antagonist ovarian stimulation protocol, for which we are uncertain of the effect of metformin on OHSS (<a href="./references#CD006105-fig-0012" title="">Analysis 1.2</a>). We are uncertain of the effect of metformin on miscarriage rates per woman and per pregnancy when compared with placebo/no treatment. </p> <p>Metformin reduced the risk of OHSS by approximately 55%, but increased the risk of side effects three‐fold. Although the reason metformin reduces the risk of OHSS is not clear, it has been hypothesised that since it decreases hyperinsulinaemia, it could also reduce the production of vascular endothelial growth factor (VEGF), one of the most important factors involved in the pathophysiology of the syndrome. In addition, metformin is associated with a statistically significant effect on oestradiol levels, an important risk factor for OHSS. </p> <p>Metformin co‐treatment appeared to decrease serum oestradiol levels on the day of hCG (<a href="./references#CD006105-fig-0021" title="">Analysis 1.11</a>), but there was no evidence that it had an effect on other ovarian stimulation parameters (number of oocytes retrieved, total dose of gonadotrophin, number of days of gonadotrophin stimulation, and cycle cancellation rate) or embryological outcomes (fertilisation rate) compared with placebo/no treatment (<a href="./references#CD006105-fig-0017" title="">Analysis 1.7</a>; <a href="./references#CD006105-fig-0018" title="">Analysis 1.8</a>; <a href="./references#CD006105-fig-0019" title="">Analysis 1.9</a>; <a href="./references#CD006105-fig-0024" title="">Analysis 1.14</a>). </p> </section> <section id="CD006105-sec-0082"> <h4 class="title">Side effects</h4> <p>Metformin may result in an increase in side effects (mostly gastrointestinal) compared with placebo/no treatment (<a href="./references#CD006105-fig-0016" title="">Analysis 1.6</a>). </p> </section> <section id="CD006105-sec-0083"> <h4 class="title">Biochemical outcomes</h4> <p>This review included studies that specifically reported reproductive outcomes in IVF/ICSI treatments where women had taken metformin in an attempt to improve reproductive profiles and conceive. We excluded studies that compared metformin with placebo or no treatment to improve metabolic or biochemical outcomes only, without attempting to conceive. We therefore cannot provide a robust analysis of the impact of metformin compared with placebo or no treatment on biochemical outcomes (serum oestradiol, androgen, and insulin levels) (<a href="./references#CD006105-fig-0021" title="">Analysis 1.11</a>; <a href="./references#CD006105-fig-0022" title="">Analysis 1.12</a>; <a href="./references#CD006105-fig-0023" title="">Analysis 1.13</a>). </p> </section> </section> <section id="CD006105-sec-0084"> <h3 class="title" id="CD006105-sec-0084">Overall completeness and applicability of evidence</h3> <p>The increased number of studies included in this updated review has improved the statistical power and external validity of our findings. Five of the 13 trials performed a priori sample size calculations to assess their primary outcome measures. A total of 1132 participants under 40 years of age were included. Eleven of the 13 included studies met the Rotterdam consensus criteria, <a href="./references#CD006105-bbs2-0042" title="Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81:19-25.">ESHRE/ASRM 2003</a>, for the diagnosis of PCOS and excluded other causes of hyperandrogenism. The only study that did not meet the Rotterdam consensus criteria may have included women with other causes of hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, and androgen‐secreting tumours) (<a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>). None of the 13 trials reported previous ovarian surgery in their baseline characteristics, and five trials did not report the cause of infertility. Twelve of the 13 trials included in this review provided data on clinical pregnancy. However, only seven trials reported live birth, and no trials reported the rate of healthy take‐home baby, which is considered by consumers to be the most important long‐term outcome of interest. The primary endpoints of the three trials (<a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>; <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a>) were either not clearly reported or were related to ovarian response parameters. </p> <p>We observed significant heterogeneity in many of the analyses. This could have been due to many factors, such as: dose and duration of metformin, different protocols of ovarian stimulation, and number of embryos transferred. However, the heterogeneity remained unchanged, even after sensitivity analysis. </p> <p>This review confirms the findings of the previous review that there is a large reduction in incidence of OHSS and a potential benefit of using metformin in long protocol GnRH‐agonist in IVF/ICSI treatments when compared with placebo or no treatment. These positive findings were not observed when metformin was used in short protocol GnRH‐antagonist. The type of ovarian stimulation protocol used in different studies, that is long protocol GnRH‐agonist or short protocol GnRH‐antagonist, is an important factor that must be discussed. <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> was included in this updated version, and this study contributed some interesting findings and raised questions that must be considered in the interpretation of data and conclusions regarding the use of metformin (especially for a short period of time) with GnRH‐antagonist. One point of discussion is the different effects of metformin co‐treatment in long protocol GnRH‐agonist and in short protocol GnRH‐antagonist. Regardless of metformin effect, it is well known that OHSS incidence in women receiving GnRH‐antagonist is significantly lower compared with the GnRH‐agonist, although there are no differences in live birth rates and clinical pregnancy rates for the two protocols (<a href="./references#CD006105-bbs2-0034" title="Al-InanyHG , YoussefMA , AboulgharM , BroekmansF , SterrenburgM , SmitJ , et al. GnRH antagonists are safer than agonists: an update of a Cochrane review. Human Reproduction Update2011;17:435.">Al‐Inany 2011</a>; <a href="./references#CD006105-bbs2-0045" title="GriesingerG , DiedrichK , TarlatzisBC , KolibianakisEM . GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reproductive Biomedicine Online2006;13:628-38.">Griesinger 2006</a>). <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> is the largest randomised, placebo‐controlled trial to study the adjuvant effect of metformin on the risk of OHSS (the study was powered to assess this outcome) using GnRH‐antagonist in IVF cycles. Surprisingly, unlike the tendency of reduction in OHSS found by <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a> (another study that used short protocol GnRH‐antagonist), metformin had no impact on the incidence of this complication in <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>. It is uncertain why this difference occurred. One possible reason is the duration of metformin pretreatment: whilst <a href="./references#CD006105-bbs2-0003" title="DoldiN , PersicoP , Di SebastianoF , MarsiglioE , FerrariA . Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer. Gynecological Endocrinology2006;22(5):235-8. ">Doldi 2006</a> used 1.5 g/day for two months, <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> chose a different approach, using a short regimen of 1.7 g/day for only 16 days. On the other hand, <a href="./references#CD006105-bbs2-0013" title="VisnovaH , VentrubaP , CrhaI , ZakovaJ . Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome [Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu]. Ceská Gynekologie2003;68(3):155-62. VisnovaH , VentrubaP , CrhaI , ZakovaJ . The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome. Human Reproduction2002;17 Suppl:180. ">Visnova 2003</a> used the shortest course of metformin, but in a long protocol GnRH‐agonist, and despite that showed a significant reduction in OHSS rate. There is a good pharmacological rationale for believing that different doses and durations of metformin co‐treatment as well as different types of ovarian stimulation protocol (different doses of gonadotrophin and different types of pituitary GnRH receptor inhibitors) will impact the outcomes differently. </p> <p>Based on our findings, routine co‐administration of metformin to PCOS women undergoing IVF/ICSI treatments may offer benefits only in cycles in which long protocol GnRH‐agonist was used in terms of increasing clinical pregnancy rate and, especially, reducing the incidence of OHSS. Few data are available regarding the effect of metformin in IVF/ICSI cycles using short protocol GnRH‐antagonist, and the results are contradictory. </p> </section> <section id="CD006105-sec-0085"> <h3 class="title" id="CD006105-sec-0085">Quality of the evidence</h3> <p>See <a href="./full#CD006105-tbl-0001">summary of findings Table 1</a>. </p> <p>We classified the quality of evidence as low for the main outcomes live birth rate (long and short protocols) and incidence of OHSS; low for the secondary outcomes clinical pregnancy rate (long protocol GnRH‐agonist), miscarriage rate, and side effects; and very low for the secondary outcome clinical pregnancy rate (short protocol GnRH‐antagonist). </p> <p>Overall, we graded only one study, <a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>, out of the 13 included studies as having low risk of bias for sequence generation, allocation concealment, and blinding (performance and detection bias). See <a href="#CD006105-fig-0002">Figure 2</a> and <a href="#CD006105-fig-0003">Figure 3</a> for the 'Risk of bias' graph and summary. The main limitations of the comparisons in this review are risk of bias and imprecision. We conducted a post hoc sensitivity analysis for our primary outcomes after noting a data discrepancy in one of the studies (<a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>), and another sensitivity analysis including only studies with low risk of bias. However, both sensitivity analyses on the studies did not substantially change our findings. </p> <p>Heterogeneity was low or moderate for the primary clinical outcomes. However, due to substantial heterogeneity between both subgroups (long and short protocols), the data for live birth and clinical pregnancy rates were pooled only according to the type of ovarian stimulation protocol. Besides that, the data for two of the laboratory outcomes (FSH dose and serum oestradiol level) were not pooled due to very high levels of unexplained heterogeneity. </p> <p>We observed extreme heterogeneity (I<sup>2</sup> = 72%; P = 0.002) when <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> was included in the live birth rate analysis. One plausible reason (amongst others) for this heterogeneity is the difference between the short and long GnRH protocol adopted. Most of the heterogeneity both in live birth rate and in clinical pregnancy rate seemed to be due to <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> which was the only study in which live birth rate and clinical pregnancy rate were higher in the placebo/no treatment group than in the metformin group. This study was powered to assess the ability of metformin to reduce OHSS as an adjunct in an IVF cycle. Consequently, <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a> was not powered to assess live birth or clinical pregnancy rates, which is another possible explanation for these inconsistencies. </p> </section> <section id="CD006105-sec-0086"> <h3 class="title" id="CD006105-sec-0086">Potential biases in the review process</h3> <p>A limitation of this review is the lack of full data from some studies, despite our attempts to obtain missing information from study authors. Whenever possible, we performed analyses based on intention‐to‐treat, to minimise bias. </p> <p>We conducted a sensitive search and are confident that we have included in the review all existing randomised trials assessing the use of metformin in PCOS women undergoing ART cycles and which reported clinically relevant outcomes (live birth rate, clinical pregnancy rate, and incidence of OHSS). </p> </section> <section id="CD006105-sec-0087"> <h3 class="title" id="CD006105-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>We are unaware of any systematic reviews evaluating the effect of metformin in women with PCOS undergoing IVF/ICSI treatment since the previous version of this review was published in 2014. The first evidence‐based international guidelines on PCOS were recently published (<a href="./references#CD006105-bbs2-0057" title="TeedeHJ , MissoML , CostelloMF , DokrasA , LavenJ , MoranL , PiltonenT , Norman RJ and International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction2018;33(9):1602-18. [PMID: 30052961]">Teede 2018</a>). These guidelines assessed the role of adjuvant metformin for women with PCOS undergoing IVF/ICSI treatment and made a conditional recommendation based on low‐quality evidence that stated: "Adjunct metformin therapy could be used before and/or during follicle stimulating hormone ovarian stimulation in women with PCOS undergoing a IVF ± ICSI therapy with a GnRH agonist protocol, to improve the clinical pregnancy rate and reduce the risk of OHSS". Our findings that the use of metformin in the long GnRH‐agonist ovarian stimulation protocol may increase the clinical pregnancy rate and may reduce the rate of OHSS would support this conditional recommendation. In addition, the guidelines made a clinical practice point that in IVF ± ICSI cycles, women with PCOS could be counselled on the potential benefits of adjunct metformin in a GnRH‐antagonist protocol to reduce risk of OHSS. Clinical practice points are made where evidence was not sought (i.e. are not evidence based) and are established where important clinical issues arose from discussion of evidence‐based or clinical consensus recommendations. In this review we are uncertain of the effect of metformin on the risk of OHSS for women with PCOS undergoing IVF/ICSI treatment. As such, this would still be consistent with the guideline clinical practice point of discussion of the potential, although uncertain, benefits of adjunct metformin in PCOS women undergoing IVF ± ICSI treatment with the GnRH‐antagonist protocol. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006105-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006105-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006105-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006105-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate per woman." data-id="CD006105-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Sensitivity analysis by excluding Palomba 2011 due to a data discrepancy (suspected risk of bias)." data-id="CD006105-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Sensitivity analysis by excluding Palomba 2011 due to a data discrepancy (suspected risk of bias). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman." data-id="CD006105-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Sensitivity analysis including only studies with low risk of bias (An 2014; Jacob 2016; Kjotrod 2004; Kjotrod 2011; Palomba 2011; Tang 2006)." data-id="CD006105-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Sensitivity analysis including only studies with low risk of bias (<a href="./references#CD006105-bbs2-0001" title="AnY , SunZ , ZhangY , LiuB , GuanY , LuM . The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical Endocrinology2014;80(3):425-31. [PMID: 23869585]">An 2014</a>; <a href="./references#CD006105-bbs2-0005" title="JacobSL , BrewerC , TangT , PictonHM , BarthJH , BalenAH . A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Human reproduction (Oxford, England)2016;31(12):2756-64. [ISRCTN21199799] [PMID: 27816925]">Jacob 2016</a>; <a href="./references#CD006105-bbs2-0007" title="KjøtrødSB , RomundstadP , vonDüringV , SundeA , CarlsenSM . Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. Fertility and Sterility2008;89(3):635-41. KjotrodS , vonDüringV , SundeA , CarlsenSM . Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study. Human Reproduction2003;18 Suppl 1:42-3. KjotrodSB , vonDüringV , CarlsenSM . Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Human Reproduction2004;19(6):1315-22. ">Kjotrod 2004</a>; <a href="./references#CD006105-bbs2-0008" title="KjotrodS , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2. Human Reproduction2010;25(Suppl 1):i286-7. KjotrodSB , CarlsenSM , RasmussenPE , Holst-LarsenT , MellembakkenJ , Thurin-KjellbergA , et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Human Reproduction2011;26(8):2045-53. [CTG: NCT00159575] [PMID: 21606131]">Kjotrod 2011</a>; <a href="./references#CD006105-bbs2-0010" title="PalombaS , FalboA , CarrilloL , VillaniMT , OrioF , RussoT , et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertility and Sterility2011;96:1384-90. [CTG: NCT01233206]">Palomba 2011</a>; <a href="./references#CD006105-bbs2-0012" title="TangT , BarthJH , BalenAH . Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment. Human Reproduction2010;25(Suppl 1):i68. TangT , GlanvilleJ , OrsiN , BarthJH , BalenAH . The use of metformin for women with PCOS undergoing IVF treatment. Human Reproduction2006;21(6):1416-25. ">Tang 2006</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman." data-id="CD006105-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Incidence of OHSS per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman." data-id="CD006105-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman." data-id="CD006105-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Clinical pregnancy rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 1: Live birth rate per woman" data-id="CD006105-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 1: Live birth rate per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 2: Incidence of OHSS per woman" data-id="CD006105-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 2: Incidence of OHSS per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 3: Clinical pregnancy rate per woman" data-id="CD006105-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 3: Clinical pregnancy rate per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 4: Miscarriage rate per woman" data-id="CD006105-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 4: Miscarriage rate per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 5: Miscarriage rate per pregnant woman" data-id="CD006105-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 5: Miscarriage rate per pregnant woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 6: Side effects per woman" data-id="CD006105-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 6: Side effects per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 7: Number of oocytes retrieved per woman" data-id="CD006105-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 7: Number of oocytes retrieved per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 8: Mean total dose of FSH (IU) per woman" data-id="CD006105-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 8: Mean total dose of FSH (IU) per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 9: Mean days of gonadotrophin per woman" data-id="CD006105-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 9: Mean days of gonadotrophin per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 10: Cycle cancellation rate (after ovulation induction)" data-id="CD006105-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 10: Cycle cancellation rate (after ovulation induction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 11: Serum oestradiol level (nmol/L) per woman" data-id="CD006105-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 11: Serum oestradiol level (nmol/L) per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0022"> <p> <div class="table" id="CD006105-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Mean or median serum androgen levels per woman</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Metformin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Onalan 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant differences in total testosterone measures from women treated with placebo (P = 0.646). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 3.1; range 2.5 to 3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 3.1; range 2.4 to 3</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tang 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone levels did not change significantly in the group taking metformin (P = 0.892); however, participants in the placebo group had a significant increase in testosterone levels (P = 0.040). In the metformin group, on the day of hCG administration, there was a significant decrease in testosterone concentration (P = 0.029) and in the free‐androgen index (P = 0.004). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline geometric mean: 2.03 nmol/l, geometric mean on the day of hCG administration: 1.97 nmol/l. Testosterone concentration (geometric mean: 1.96 nmol/l). Free‐androgen index (geometric mean: 2.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline geometric mean: 2.06 nmol/l, geometric mean on the day of hCG administration: 2.52 nmol/l. Testosterone concentration (geometric mean: 2.52 nmol/l). Free‐androgen index (geometric mean: 3.34) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 12: Mean or median serum androgen levels per woman </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0022">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006105-fig-0023"> <p> <div class="table" id="CD006105-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Mean or median fasting insulin and glucose levels per woman</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Metformin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Onalan 2005</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were no significant changes in the glucose/insulin ratio between groups (P = 0.81). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 6; range 2.4 to 8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 6; range 3 to 10</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tang 2006</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were no significant changes in the insulin sensitivity test (QUICKI) between baseline and the day of oocyte retrieval in the metformin group (P = 0.200) and the placebo group (P = 0.572). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 0.377</p> <p>At the day of oocyte retrieval: 0.417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 0.386</p> <p>At the day of oocyte retrieval: 0.400</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 13: Mean or median fasting insulin and glucose levels per woman </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD006105-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 14: Fertilisation rate" data-id="CD006105-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 14: Fertilisation rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006105-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/urn:x-wiley:14651858:media:CD006105:CD006105-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metformin versus placebo or no treatment, Outcome 15: Sensitivity analysis live birth by excluding Palomba 2011 due to a data discrepancy (suspected risk of bias)" data-id="CD006105-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_t/tCD006105-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Metformin versus placebo or no treatment, Outcome 15: Sensitivity analysis live birth by excluding Palomba 2011 due to a data discrepancy (suspected risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/media/CDSR/CD006105/image_n/nCD006105-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006105-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to placebo or no treatment in women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metformin compared to placebo or no treatment in women with polycystic ovary syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with polycystic ovary syndrome<br/><b>Setting:</b> Human reproduction center<br/><b>Intervention:</b> metformin<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with metformin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Live birth rate per woman ‐ long protocol GnRH‐agonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.30<br/>(0.94 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>651<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence for the effect of metformin on live birth rate per woman ‐ long protocol GnRH‐agonist is uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000<br/>(266 to 507) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Live birth rate per woman ‐ short protocol GnRH‐antagonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/>(0.29 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may reduce live birth rate per woman ‐ short protocol GnRH‐antagonist.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000<br/>(126 to 343) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incidence of OHSS per woman</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.46<br/>(0.29 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1091<br/>(11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may reduce incidence of OHSS per woman.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>196 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/>(57 to 141) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical pregnancy rate per woman ‐ long protocol GnRH‐agonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(1.08 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>915<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may increase clinical pregnancy rate per woman ‐ long protocol GnRH‐agonist.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>363 per 1000<br/>(297 to 449) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical pregnancy rate per woman ‐ short protocol GnRH‐antagonist</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.38<br/>(0.21 to 9.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>177<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>5 6 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence for the effect of metformin on clinical pregnancy rate per woman ‐ short protocol GnRH‐antagonist is uncertain. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>612 per 1000<br/>(93 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Miscarriage rate per woman</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.56 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>821<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The evidence for the effect of metformin on miscarriage rate per woman is uncertain.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(59 to 141) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Side effects per woman</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.35<br/>(2.34 to 4.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>748<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Metformin may result in an increase in side effects per woman.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(207 to 424) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>GnRH:</b> gonadotrophin‐releasing hormone; <b>OHSS:</b> ovarian hyperstimulation syndrome; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Evidence downgraded by one level for serious risk of bias: the majority of the RCTs have unclear or high risk of bias.<br/><sup>2</sup>Evidence downgraded by one level for serious imprecision: low number of events (total number of events &lt; 300) and 95% CI includes both appreciable effect and little or no effect.<br/><sup>3</sup>Evidence downgraded by two levels for very serious imprecision: low number of events (total number of events &lt; 300) and data based on one small RCT.<br/><sup>4</sup>Evidence downgraded by one level for serious imprecision: low number of events (total number of events &lt; 300).<br/><sup>5</sup>Evidence downgraded by one level for serious risk of bias: all studies considered as at unclear risk of bias for at least one domain.<br/><sup>6</sup>Evidence downgraded by two levels for serious inconsistency (I<sup>2</sup> = 87%) as unexplained heterogeneity (i.e. heterogeneity not explained by subgrouping of data according to stimulation protocol).<br/><sup>7</sup>Evidence downgraded by two levels for very serious imprecision: low number of events (total number of events &lt; 300) and data based on two RCTs, and 95% CI includes both appreciable benefit and harm.<br/><sup>8</sup>Evidence downgraded by one level for serious imprecision: low number of events (total number of events &lt; 300), and 95% CI includes both appreciable benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Metformin compared to placebo or no treatment in women with polycystic ovary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/full#CD006105-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006105-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Live birth rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.94, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.29, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Incidence of OHSS per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.29, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.26, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.32, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Clinical pregnancy rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.08, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.21, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>821</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.56, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.43, 5.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Miscarriage rate per pregnant woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.51, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.80, 7.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Side effects per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.35 [2.34, 4.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.07 [1.79, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [1.92, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Number of oocytes retrieved per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐1.42, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐1.44, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐3.76, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Mean total dose of FSH (IU) per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.23, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐0.28, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.28, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Mean days of gonadotrophin per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.71, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.89, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.04, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Cycle cancellation rate (after ovulation induction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.43, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.33, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.25, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Serum oestradiol level (nmol/L) per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.43 [‐4.59, ‐0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.21 [‐4.75, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.56 [‐5.30, ‐1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Mean or median serum androgen levels per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Mean or median fasting insulin and glucose levels per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Fertilisation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.78 [‐12.21, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐11.38, 12.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.40 [‐14.96, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Sensitivity analysis live birth by excluding Palomba 2011 due to a data discrepancy (suspected risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Long protocol GnRH‐agonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.91, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Short protocol GnRH‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.29, 0.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006105.pub4/references#CD006105-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006105.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006105-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006105-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006105-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006105-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD006105-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD006105-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD006105-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD006105-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006105-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006105-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006105\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006105\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006105\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006105\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006105\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006105.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006105.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006105.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006105.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006105.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729360033"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006105.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729360037"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006105.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edafce87ef4a4',t:'MTc0MDcyOTM2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 